Is your drug candidate struggling with solubility, slowing down its path to market? Discover how Amorphous Solid Dispersions (ASDs) can be your breakthrough solution, from early development to commercial success.
In this insightful on-demand webinar, Lonza expert David Lyon shares key capabilities for screening ASD potential in preclinical studies and optimizing their commercial applicability.
You'll learn how to:
- Strategically evaluate ASDs for your early-phase compounds.
- Bridge the gap from preclinical screens to successful commercialization.
- Accelerate your poorly soluble drug's journey to patients.
Don't let solubility challenges hold you back. Watch now to transform your drug development pipeline!